Screener
TG Therapeutics TGTX Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: TG Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025955
| Line item | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 |
|---|---|---|
| Financing costs paid | (2,598) | — |
| Purchase of treasury stock | (99,992) | (12,998) |
| Net cash provided by (used in) financing activities | 390,914 | (12,545) |
| NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | 403,449 | (50,750) |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF PERIOD | 80,490 | 181,192 |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD | $483,939 | $130,442 |
| Reconciliation to amounts on condensed consolidated balance sheets: | ||
| Cash and cash equivalents | $482,575 | $129,126 |
Document
FAQ
- What is TG Therapeutics's net change in cash?
- TG Therapeutics (TGTX) reported net change in cash of $40.38M in Q2 2026.
- How has TG Therapeutics's net change in cash changed year-over-year?
- TG Therapeutics's net change in cash increased by 1446.4% year-over-year, from -$3M to $40.38M.
- What is the long-term trend for TG Therapeutics's net change in cash?
- Over 2 years (2021 to 2025), TG Therapeutics's net change in cash has grown at a -35.5% compound annual growth rate (CAGR), from -$254.55M to -$105.78M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about TG Therapeutics's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude